Bone Reports最新文献

{"title":"VEGF-A, -C, -D, VEGFR1, -2, -3, PDGF-BB and FGF-2 join forces to induce vascular and lymphatic angiogenesis during bone healing of hip implants","authors":"Jean Cassuto ,&nbsp;Agnetha Folestad ,&nbsp;Jan Göthlin ,&nbsp;Henrik Malchau ,&nbsp;Johan Kärrholm","doi":"10.1016/j.bonr.2025.101856","DOIUrl":"10.1016/j.bonr.2025.101856","url":null,"abstract":"<div><h3>Introduction</h3><div>Angiogenic growth factors are a critical part of bone repair and regeneration in the aftermath of bone trauma. In the current study we monitored the spatiotemporal responses of angiogenic factors and receptors during the process of osseointegration of hip implants.</div></div><div><h3>Materials and methods</h3><div>Twenty-four patients having undergone primary total hip arthroplasty (THA) due to one-sided osteoarthritis (OA) were monitored during a period of 18 years (Y) by repeated measurements of plasma biomarkers as well as clinical and radiographic variables, the latter two showing all implants of the study to be well anchored throughout the follow-up. Eighty-one healthy donors divided into three gender- and age-matched subgroups and twenty OA patients awaiting THA, served as controls. Plasma was analyzed for vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-D, vascular endothelial growth factor receptor 1 (VEGFR1) or sFlt-1, VEGFR2 (KDR/sFlk-1), VEGFR3 (sFlt-4), platelet derived growth factor–BB (PDGF-BB), fibroblast growth factor-2 (FGF-2) and placental growth factor (PIGF). Analysis of biomarkers was done by means of a high-sensitivity and wide dynamic range electrochemiluminescence technique allowing for detection of low levels and minor changes in biomarker levels. Spatiotemporal changes of biomarkers in THA patients during the follow-up were presented in the context of the four phases of endochondral bone repair.</div></div><div><h3>Results</h3><div>VEGF-A, VEGFR1, PDGF-BB and FGF-2 were significantly higher, whereas VEGF-C was significantly lower in presurgery OA patients versus healthy subjects but were all normalized shortly after implant surgery. VEGF-A, VEGF-C, VEGF-D, VEGFR2, VEGFR3, FGF-2 and PDGF-BB increased sharply 1–2 Y post-implant and reached a peak significantly above healthy control subjects at 5–7 Y after implant insertion before returning to control level 13-15Y post-surgery, except for VEGF-D that returned to control level at 7Y post-implant. VEGFR1 decreased to the level of healthy subjects at 6 W post-THA and remained there throughout the study. PIGF did not differ from healthy subjects at any point during the follow-up.</div></div><div><h3>Conclusion</h3><div>Increased levels of VEGF-A, VEGFR1, PDGF-BB and FGF-2 and reduced VEGF-C in presurgery OA relative healthy subjects support a cartilage protective or disease-inducing role in osteoarthritis. The concerted increase by all proangiogenic factors of the study, except VEGFR1 and PIGF, at 5 Y post-implant lend strong support to this being the phase of bone repair when blood and lymph vessels invade the avascular calcified hypertrophic cartilage and trigger its remodeling into bone in hip arthroplasty patients.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101856"},"PeriodicalIF":2.1,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluorescent collagen hybridizing peptide for quantifying collagen denaturation in cortical bone","authors":"William Woolley ,&nbsp;Naomi Chin ,&nbsp;S. Michael Yu ,&nbsp;Claire Acevedo","doi":"10.1016/j.bonr.2025.101855","DOIUrl":"10.1016/j.bonr.2025.101855","url":null,"abstract":"<div><div>Bone fracture risk is clinically assessed with bone mineral density (BMD); however, individuals with normal BMD also experience fractures, highlighting the need for complementary fracture risk assessment tools. While BMD remains the clinical gold standard, it fails to capture bone quality factors that contribute to fragility. Among these, collagen quality is essential for bone toughness, as it allows collagen to dissipate energy via stretching and uncoiling. When collagen is denatured, it loses its ability to deform, increasing fracture risk. This process is particularly relevant in aging, osteoporosis, and metabolic conditions such as diabetes, yet no clinical methods exist to quantify or localize denatured collagen in mineralized bone. This study introduces Collagen Hybridizing Peptide (CHP) as a tool to quantify denatured collagen in cortical bone. Here, we show that CHP fluorescence correlates strongly with collagen denaturation measured by established trypsin-hydroxyproline assay (r² = 0.99) when applied to mineralized tissue subjected to heat treatment or mechanical loading. Confocal microscopy revealed a 55 % increase in collagen denaturation when tissue strain exceeded the yield point (<em>p</em> <em>&lt;</em> 0.05). Our findings demonstrate that fluorescent CHP localizes high-strain regions to collagen denaturation on bone fracture surfaces, indicating that collagen damage occurs during post-yield failure. This non-destructive technique offers a powerful tool for assessing collagen quality, with potential applications in osteoporosis, diabetic bone fragility, and aging research. By advancing our ability to evaluate bone quality in cortical bone, R-CHP provides new method to study how denatures collagen affects bone resistance to fracture.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101855"},"PeriodicalIF":2.1,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144501282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"p75NTR regulates postnatal skeletal development via NGF-responsive JNK signaling","authors":"Chiho Kadota-Watanabe ,&nbsp;Jinsook Suh ,&nbsp;Zhenqing Liu ,&nbsp;Eric Yin ,&nbsp;Kate Lindsey ,&nbsp;Isabelle Lao-Ngo ,&nbsp;Byron Zhao ,&nbsp;Jonathan H. Wu ,&nbsp;In Won Chang ,&nbsp;Reuben H. Kim ,&nbsp;Ophir D. Klein ,&nbsp;Christine Hong","doi":"10.1016/j.bonr.2025.101854","DOIUrl":"10.1016/j.bonr.2025.101854","url":null,"abstract":"<div><div>p75^NTR has emerged as a key regulator of skeletal development and bone homeostasis. To define its role, we characterized skeletal phenotypes in global and mesenchyme-specific <em>p75</em>^<em>NTR</em> knockout mouse models. Global deletion of <em>p75</em>^<em>NTR</em> resulted in postnatal growth retardation, decreased trabecular and cortical bone mass, and impaired growth plate architecture—hallmarks of an osteoporotic phenotype that persisted into adulthood. Conditional deletion of <em>p75</em>^<em>NTR</em> in mesenchymal progenitor cells using Prx1-Cre recapitulated these skeletal deficits, confirming a cell-autonomous role in bone development. In vitro, bone marrow stromal cells (BMSCs) derived from <em>p75</em>^<em>NTR</em>-deficient mouse exhibited diminished osteogenic differentiation capacity, reduced mineralization, and downregulation of key osteogenic genes. Transcriptomic profiling revealed significant suppression of the NGF-MAPK/AP-1 signaling axis in <em>p75</em>^<em>NTR</em>-deficient BMSCs. Functional studies demonstrated that loss of <em>p75</em>^<em>NTR</em> reduced JNK pathway activation and downstream epigenetic regulators, including <em>Kdm4b</em> and its target gene <em>Dlx5</em>. Overexpression of <em>Kdm4b</em> rescued mineralization defects and restored osteogenic gene expression in <em>p75</em>^<em>NTR</em>-deficient BMSCs, establishing a mechanistic link between p75^NTR signaling and osteoblast differentiation. These findings define the NGF–p75^NTR–JNK–KDM4B<em>–Dlx5</em> axis as a central regulatory pathway in postnatal bone growth and osteogenesis. Given the critical role of p75^NTR in skeletal development and bone homeostasis, targeted modulation of this signaling cascade may represent a promising therapeutic approach for treating osteoporosis and other bone disorders.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"26 ","pages":"Article 101854"},"PeriodicalIF":2.1,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144322046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlations between 6-minute walk test, chair-rise test, and lower extremity functional scale among patients with hypophosphatasia","authors":"Lothar Seefried,&nbsp;Franca Genest","doi":"10.1016/j.bonr.2025.101853","DOIUrl":"10.1016/j.bonr.2025.101853","url":null,"abstract":"<div><h3>Purpose</h3><div>Hypophosphatasia (HPP) is a rare disease characterized by skeletal and nonskeletal manifestations that can increase patient disability. The 6-Minute Walk Test (6MWT) is frequently used to assess mobility in patients with HPP, although the test is laborious to conduct in clinical practice. The purpose of the current study was to determine correlations between time to complete the 6MWT, time to complete the Chair-Rise Test (CRT), and scores on the Lower Extremity Functional Scale (LEFS) in adults with HPP.</div></div><div><h3>Methods</h3><div>Pearson correlations between time to complete outcomes on the 6MWT and CRT, time to complete the 6MWT and scores on the LEFS, and time to complete the CRT and scores on the LEFS were calculated using de-identified data from adults with HPP who had first onset of symptoms in childhood. All patients were enrolled in the previously conducted, observational EmPATHY study.</div></div><div><h3>Results</h3><div>Pearson correlation analyses showed inverse correlations between 6MWT and CRT outcomes (<em>r</em> = −0.584) and between CRT and LEFS outcomes (<em>r</em> = −0.596) and a direct correlation between 6MWT and LEFS outcomes (<em>r</em> = 0.808).</div></div><div><h3>Conclusions</h3><div>Time to complete the 6MWT was correlated with time to complete the CRT and scores on the LEFS in adults with HPP. CRT and LEFS may be suitable, expeditious options to amend or substitute 6MWT when assessing functional status in patients with HPP.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"25 ","pages":"Article 101853"},"PeriodicalIF":2.1,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144167867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning-assisted classification of hip conditions in pediatric cerebral palsy patients using migration percentage measurements","authors":"Sema Ertan Birsel ,&nbsp;Ekrem Demirci ,&nbsp;Ali Seker ,&nbsp;Kadriye Yasemin Usta Ayanoğlu ,&nbsp;Emir Oncu ,&nbsp;Fatih Ciftci","doi":"10.1016/j.bonr.2025.101852","DOIUrl":"10.1016/j.bonr.2025.101852","url":null,"abstract":"<div><div>Hip displacement is a significant concern in children with cerebral palsy (CP), necessitating accurate and timely assessment to prevent long-term complications. This study developed a support vector machine (SVM) model to classify hip conditions using migration percentage (MP) measurements obtained from 176 hips across 88 anteroposterior pelvic radiographs. MP values were categorized into three groups: normal (MP ≤ 30 %), risky (30 % &lt; MP ≤ 60 %), and dislocated (MP &gt; 60 %). The SVM model was evaluated using stratified k-fold cross-validation, with accuracy, precision, recall, and F1-scores as key metrics. Its classifications were compared to manual evaluations performed by an orthopedic resident and a pediatric orthopedic surgeon. The model achieved an overall accuracy of 92.898 %, surpassing the consistency and reliability of manual assessments, particularly in identifying dislocated hips. Statistical analysis showed no significant differences between the model's MP measurements and those of the clinicians, validating its effectiveness. This study highlights the potential of SVM models to enhance diagnostic accuracy, reduce variability in evaluations, and support clinical decision-making. Future research should expand the dataset and incorporate advanced machine learning models to further improve diagnostic precision.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"25 ","pages":"Article 101852"},"PeriodicalIF":2.1,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144099602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevention of osteoporotic vertebral fractures in eastern and in western countries","authors":"Fjorda Koromani ,&nbsp;Jiawei Li ,&nbsp;Hiroshi Hagino ,&nbsp;Richard Eastell ,&nbsp;Annegreet Vlug ,&nbsp;Ling Wang ,&nbsp;Hua Yue ,&nbsp;Yong-Chan Ha ,&nbsp;Steven Cummings ,&nbsp;Salvatore Minisola ,&nbsp;Claus-C. Glüer ,&nbsp;Ling Oei ,&nbsp;the East Meets West Action Group of the European Calcified Tissue Society","doi":"10.1016/j.bonr.2025.101851","DOIUrl":"10.1016/j.bonr.2025.101851","url":null,"abstract":"<div><div>Osteoporotic vertebral fractures (VFs) are among the most common and clinically significant manifestations of skeletal fragility, contributing substantially to morbidity, disability, and future fracture risk worldwide. Yet, their recognition and management remain inconsistent across regions. To explore differences and similarities in the prevalence, diagnosis, management, and prevention of vertebral fractures, the East Meets West (EmW) Action Group of the European Calcified Tissue Society convened a multi-country exchange among clinical and research experts from Europe, the USA, and East Asia. This report summarizes the discussions and synthesizes current knowledge on the topic. Evidence from China, South Korea, Japan, and Germany shows a wide range in reported VF prevalence and incidence, largely influenced by differences in population aging, imaging access, and diagnostic adjudication methods. While lateral spine radiographs remain the standard for detection in both research and clinical care, variable use of quantitative morphometry (QM), semi-quantitative (SQ), and algorithm-based qualitative (ABQ) methods limits comparability. MRI remains the gold standard for assessing fracture acuity, but is not feasible for widespread screening. VFA via DXA is gaining popularity, although underutilized in several settings. Despite the availability of effective pharmacologic treatments, including bisphosphonates, denosumab, and anabolic agents, treatment rates following VF remain suboptimal across all countries studied. None of the countries currently has a nationwide vertebral fracture screening program, although fracture liaison services (FLS) and AI-assisted imaging offer promising pathways forward. The lack of a universally accepted definition and gold standard for VF adjudication continues to hamper clinical decision-making and data harmonization. This report highlights the need for greater international consensus on diagnostic criteria, improved integration of vertebral fracture screening into clinical workflows, and the development of targeted strategies to close treatment gaps and reduce the global burden of vertebral fractures.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"25 ","pages":"Article 101851"},"PeriodicalIF":2.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of endurance exercise and dietary protein intake on osteokine, bone turnover, and inflammatory markers in endurance runners: A narrative review","authors":"Sofia Valente Ferreira ,&nbsp;Silar Gardy ,&nbsp;Tyler A. Churchward-Venne ,&nbsp;Andrea R. Josse ,&nbsp;Jenna C. Gibbs","doi":"10.1016/j.bonr.2025.101850","DOIUrl":"10.1016/j.bonr.2025.101850","url":null,"abstract":"<div><div>Bone stress injuries are pervasive among endurance runners due to repetitive sport-specific mechanical loading and a higher prevalence of low energy availability (i.e., inadequate dietary energy intake relative to exercise energy expenditure). Chronic endurance exercise promotes bone formation, thus, runners typically have higher bone mineral density (BMD) than non-weightbearing athletes and sedentary individuals. However, runners may experience increased bone resorption for hours to days following an endurance exercise bout. If recovery is insufficient, uncoupled bone turnover can pose a significant risk to their bone health. While skeletal-immune system crosstalk has been studied, the interaction during and after exercise in athletes is an emerging area of research. Nutritional interventions have been investigated for their effects on bone metabolism surrounding exercise. However, limited research has examined dietary protein intake in endurance athletes, particularly concerning its effects on bone metabolism and osteoimmunology. This narrative review provides an overview of the evidence on the effects of endurance exercise and dietary protein intake on osteokines, bone turnover, and inflammatory markers in endurance athletes. Acute bouts of high-intensity running increase osteokines and bone turnover markers that promote bone resoprtion which parallels increases in pro-inflammatory markers in endurance athletes, suggesting crosstalk between these systems during and after exercise. Chronic endurance exercise promotes increased resting levels of bone formation, while reducing resting pro-inflammatory markers. Adequate dietary protein ingestion habitually and pre-, during, and post-exercise may attenuate bone resportion and pro-inflammatory markers in endurance athletes.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"25 ","pages":"Article 101850"},"PeriodicalIF":2.1,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143941867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of skeletal fragility due to Loeys-Dietz syndrome and treatment with romosozumab followed by denosumab","authors":"Yasutaka Tsujimoto ,&nbsp;Naoki Yamamoto ,&nbsp;Hayato Fukumitsu ,&nbsp;Hironori Bando ,&nbsp;Masaaki Yamamoto ,&nbsp;Keiko Tanaka ,&nbsp;Naoya Morisada ,&nbsp;Miwako Nagasaka ,&nbsp;Keisuke Oe ,&nbsp;Takahiro Niikura ,&nbsp;Mika Yamauchi ,&nbsp;Wataru Ogawa ,&nbsp;Hidenori Fukuoka","doi":"10.1016/j.bonr.2025.101849","DOIUrl":"10.1016/j.bonr.2025.101849","url":null,"abstract":"<div><div>Loeys–Dietz syndrome (LDS) is an autosomal dominant, inherited connective tissue disorder caused by a pathogenic variant in TGF-β signaling-related genes. LDS is associated with a high risk of low bone mineral density (BMD) and fractures.</div><div>We present a case report of a 43-year-old premenopausal woman with skeletal fragility who was diagnosed with LDS type 4 due to a large heterozygous deletion in the <em>TGFB2</em> gene. Upon initial referral, she was evaluated for secondary osteoporosis. Although mild abnormalities in calcium metabolism, menstrual irregularities, and lack of exercise were observed, they were not associated with this condition. However, a thorough family history and physical examination raised the suspicion of Marfan syndrome and related disorders, which were subsequently confirmed using genetic testing. Treatment with romosozumab for 1 year increased the lumbar spine BMD from 0.750 g/cm² (<em>Z</em>-score −2.1) to 0.881 g/cm² (<em>Z</em>-score −1.0) and the femoral neck BMD from 0.407 g/cm² (Z-score − 3.0) to 0.428 g/cm² (Z-score − 2.6), with a slight increase in total hip BMD from 0.525 g/cm² (<em>Z</em>-score −2.6) to 0.527 g/cm² (<em>Z</em>-score −2.4). Subsequent therapy with denosumab for 1 year further improved the lumbar spine BMD to 0.939 g/cm² (Z-score, −0.5), femoral neck BMD to 0.496 g/cm² (Z-score, −2.0), and total hip BMD to 0.552 g/cm² (Z-score, −2.2). To our knowledge, this is the first case report of an improvement in BMD with romosozumab, followed by denosumab, for skeletal fragility due to LDS. Our findings suggest that this treatment regimen may be an effective therapeutic option for the management of skeletal fragility in patients with LDS.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"25 ","pages":"Article 101849"},"PeriodicalIF":2.1,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteosarcopenia as a risk factor for depression: Longitudinal findings from the SHARE study","authors":"Nicola Veronese ,&nbsp;Francesco Saverio Ragusa ,&nbsp;Shaun Sabico ,&nbsp;Ligia Juliana Dominguez ,&nbsp;Mario Barbagallo ,&nbsp;Gustavo Duque ,&nbsp;Lee Smith ,&nbsp;Nasser Al-Daghri","doi":"10.1016/j.bonr.2025.101848","DOIUrl":"10.1016/j.bonr.2025.101848","url":null,"abstract":"<div><h3>Background</h3><div>Osteosarcopenia (i.e., the co-existence of osteoporosis and sarcopenia) and depression are highly prevalent among older people. However, the association between osteosarcopenia and depression in older people is largely unknown. Therefore, the present study aims to investigate this possible association in a representative sample of the older adult population in Europe and Israel.</div></div><div><h3>Methods</h3><div>Osteosarcopenia was defined as the concomitant presence of osteoporosis and sarcopenia; depressive symptoms in the SHARE study were self-reported using the EURO-D scale. The association between the presence of osteosarcopenia at baseline in people free from depression and incident depression during 12 years of follow-up was analyzed using a Cox's regression analysis, adjusting for several baseline covariates.</div></div><div><h3>Results</h3><div>16,452 participants were included (mean age 63.7, SD 9.6; females 50.6 %). During the follow-up period, 5056 participants (31.1 % of the initial population) became depressed. People affected by osteosarcopenia became depressed in more than half of the cases compared to a quarter of controls. After adjusting for several potential baseline confounding variables, only sarcopenia (HR, hazard ratio = 1.17; 95 % CI, confidence intervals 1.04–1.32; <em>p</em> = 0.009) and osteosarcopenia (HR = 1.27; CI 95 % 1.12–1.58; <em>p</em> = 0.003) were significantly associated with a higher risk of depression.</div></div><div><h3>Limitations</h3><div>Definition of sarcopenia using an anthropometric equation; definition of depression using the EURO-D scale.</div></div><div><h3>Conclusions</h3><div>The present study identified a significant association between osteosarcopenia and depression over 12 years of follow-up, mainly driven by sarcopenia. If future research confirms the present findings, it may then be prudent to target those with osteosarcopenia to aid in the prevention of onset depression.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"25 ","pages":"Article 101848"},"PeriodicalIF":2.1,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination or sequential teriparatide for osteoporosis treatment in denosumab-users: real-world bone mineral density outcomes","authors":"Shejil KUMAR ,&nbsp;Courtney STREETER ,&nbsp;Michelle M. MCDONALD ,&nbsp;Roderick J. CLIFTON- BLIGH ,&nbsp;Matti L. GILD ,&nbsp;Christian M. GIRGIS","doi":"10.1016/j.bonr.2025.101847","DOIUrl":"10.1016/j.bonr.2025.101847","url":null,"abstract":"<div><div>The optimal osteoanabolic strategy in denosumab (Dmab)-users remains uncertain. In treatment-naïve patients, Dmab/teriparatide (TPTD) combinations result in dramatic bone mineral density (BMD) gains at the spine and hip. However, BMD outcomes with combination Dmab/TPTD have not been investigated in patients on <em>established</em> Dmab.</div><div>We retrospectively reviewed patients with osteoporosis at two Sydney centers between 2013 and 2023. Eligible patients were managed with Dmab immediately before ≥12-months TPTD. Patients were grouped according to whether TPTD was added to ongoing Dmab (<em>combination</em>) or Dmab was withheld during TPTD (<em>sequence</em>). BMD outcomes were assessed during TPTD.</div><div>The total cohort (<em>N</em> = 23; 11 = combination, 12 = sequence) had mean age 77 ± 7 years and were predominantly female (87 %). Overall, prior vertebral (52 %) and non-vertebral fractures (2.4 ± 1.5) were prevalent and pre-TPTD BMD T-scores (SD) low at lumbar spine (−2.4 ± 1.2) and total hip (−2.2 ± 0.6). Median Dmab exposure was 5-doses (IQR 3–11), median overall antiresorptive exposure was 6-years (IQR 4–11) and majority (&gt;90 %) received 18-months TPTD. Groups were similar in age, sex, Dmab and overall antiresorptive exposure, fracture prevalence, DXA interval and pre-TPTD BMD values. Combination Dmab/TPTD was associated with significant lumbar spine BMD gains (+0.080 g/cm² ± 0.059 g/cm², <em>p</em> = 0.004; +9.8 %). No significant BMD change occurred during sequential Dmab/TPTD (+0.026 g/cm² ± 0.049 g/cm², <em>p</em> = 0.107; +3.5 %). Combination Dmab/TPTD resulted in greater lumbar spine BMD gains (<em>p</em> = 0.039). Hip and femoral neck BMD remained stable in both groups.</div><div>In this retrospective study, significant lumbar spine BMD gains occurred during combined Dmab/TPTD in patients on established Dmab. These results warrant prospective controlled studies to further inform optimal osteoanabolic strategies in Dmab-users.</div></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"25 ","pages":"Article 101847"},"PeriodicalIF":2.1,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143879309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}